Zevra Therapeutics
ZVRA
58 hedge funds and large institutions have $107M invested in Zevra Therapeutics in 2016 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 4 closing their positions.
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
21% more funds holding
Funds holding: 48 → 58 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
23% less capital invested
Capital invested by funds: $139M → $107M (-$32.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.81M |
| 2 |
DA
DSC Advisors
Chicago,
Illinois
|
+$1.4M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$979K |
| 4 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
+$866K |
| 5 |
BG
BlackRock Group
London,
United Kingdom
|
+$619K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$6.55M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.36M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$1.22M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$508K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$158K |
ZVRA Hedge Fund Activity: Q1 2016 in Review
58 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q1 2016, worth a combined $107M — down 23% from $139M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ZVRA positions and 4 closed out — a net gain of 10 holders — while 20 added to existing stakes and 12 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4.81M. The largest seller was Broadfin Capital, cutting an estimated $6.55M.
- 58 institutional investors held Zevra Therapeutics (ZVRA) as of Q1 2016, up from 48 in Q4 2015.
- Funds reported $107M of Zevra Therapeutics stock for Q1 2016, down 23% quarter-over-quarter.
- 14 funds opened new Zevra Therapeutics positions in Q1 2016 and 4 closed out, a net change of +10 holders.
- The largest Zevra Therapeutics buyer in Q1 2016 was Point72 Asset Management, an estimated $4.81M added.
- The largest Zevra Therapeutics seller in Q1 2016 was Broadfin Capital, an estimated $6.55M sold.
Based on aggregated 13F filings for Q1 2016.